Navigation Links
12-month ATLANTA trial data show sustained benefit of Catania Stent
Date:10/14/2008

WASHINGTON, Oct. 13 -- Clinical investigators at today's "Innovative Devices and Futuristic Therapies" session during the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, presented 12-month follow-up data from the ATLANTA Trial. The results include zero percent thrombosis in patients discontinuing dual anti-platelet therapy after only 30 days.

The ATLANTA Trial is a first-in-man (FIM), prospective, single center, non-randomized, single-arm study involving 55 patients (76 lesions) treated with the CATANIA™ Coronary Stent System with NanoThin Polyzene®-F surface modification for symptomatic ischemic heart disease due to de novo, obstructive lesions of native coronary arteries. The trial was sponsored by CeloNova BioSciences, Inc., maker of the CATANIA™ stent.

At 12 months, in an unusually complex FIM patient population, the results showed zero (0.0) percent stent thrombosis (Academic Research Consortium, or ARC-defined), death, myocardial infarction, stroke, or coronary artery bypass graft. Target lesion revascularization was 10.9 percent (only 3.6 percent clinically driven, 7.3 percent non-clinically driven), with a binary restenosis rate of 6.8 percent (five of 74 lesions analyzed at twelve months). Of note, all patients stopped dual anti-platelet therapy after 30 days, but continued aspirin (100 mg/d) throughout the 12-month period.

The acute angiographic and procedural success rate in the ATLANTA Trial was 100 percent. Independent core laboratories analyzed quantitative coronary angiography and intravascular ultrasound (IVUS) data for all patients immediately after stent implantation and at 6-month follow-up. Further analysis of 1,904 cross sections (19,028 struts) by investigators using Optimal Coherence Tomography at baseline and again at 6-month follow-up in a subset of 15 randomly selected patients revealed complete endothelialization and 99.5 percent stent strut coverage.

"Every clinician is aware of the questions and issues surrounding drug-eluting stents and the increased risk of late and very late stent thrombosis, malapposition, inflammatory or hypersensitivity reactions, as well as the economic impact of maintaining long-term dual antiplatelet therapy," said Corrado Tamburino, MD, PhD, FESC, FSCAI, FSICI-GISE, Professor of Cardiology and Chief of the Cardiovascular Department, Ferrarotto Hospital, Catania, Italy, and lead investigator in the ATLANTA Trial. "The 12-month ATLANTA data indicate that the CATANIA™ stent with Polyzene®-F is truly a new and promising class of stent. Further, the CATANIA™ stent may offer an improved safety profile as evidenced by the fact that there were no deaths, myocardial infarctions, or stent thrombosis in a significantly complex patient population. Economically, this stent has merit, because it does away with the costs associated with long-term dual antiplatelet therapy."

The rapid-exchange, cobalt-chromium CATANIA™ stent carries a CE Mark and is currently available for sale outside of the United States in 60 sizes, in lengths from 8-38mm and in diameters from 2.0-4.0mm. "The CATANIA™ stent represents the next evolution in angioplasty treatment," said Thomas A. Gordy, President and Chief Executive Officer, CeloNova Biosciences, Inc. "Physicians, health care systems, and insurance programs need breakthroughs, not devices that are marginally better than what already exists. Marginal improvements advance competition; we need to be advancing medicine first."

The CATANIA™ stent surface has a thin (35-40 nanometers) surface treatment of highly lubricious Polyzene®-F, a synthesized, inorganic, biocompatible polymer that is anti-thrombotic, anti-inflammatory, bacterial-resistant, and essentially cloaks the device's presence from the body to promote healthy endothelial cell growth without stimulating platelet activation.

"We found the CATANIA™ stent to be highly deliverable, trackable, and flexible in even the most tortuous anatomy," said Dr. Tamburino. "The Polyzene®-F surface treatment endows the stent with exceptional qualities that not only create a highly lubricious system that inspires user confidence and improved pushability, but also hides the stent from the body's defenses, which reduces platelet aggregation and the potential for thrombosis."


'/>"/>

Contact: David Patti
dpatti@storchmurphy.com
908-276-0777
The Storch Murphy Group
Source:Eurekalert

Related biology news :

1. DHS Begins Collecting 10 Fingerprints From International Visitors at Hartsfield-Jackson Atlanta International Airport
2. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
3. Vitamin E trials fatally flawed
4. Research team says extraterrestrial impact to blame for Ice Age extinctions
5. Trial seeks genetic fingerprint for predicting drug effectiveness
6. The industrial space age
7. Contrast agent trials in swine
8. Small-scale fishing in Mexico rivals industrial fisheries in accidental turtle deaths
9. Study of African traditional medicine will begin world-first clinical trial
10. New model revises estimates of terrestrial carbon dioxide uptake
11. New clinical trial results show how personalized medicine will alter treatment of genetic disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/16/2016)... 2016 Sensory Inc ., a ... for consumer electronics, and VeriTran , a ... industry, today announced a global partnership that will ... authenticate users of mobile banking and mobile payments ... software which requires no specialized biometric scanners, yet ...
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):
(Date:12/8/2016)...  Renova™ Therapeutics, a biotechnology company developing gene ... 2 diabetes, announced that it has obtained a ... vector developed in the laboratory of Professor ... The company plans to use this vector in ... "Early research has shown promise ...
(Date:12/8/2016)... Oxford Gene Technology (OGT), ... panel range with the launch of the SureSeq myPanel™ NGS ... variants in familial hypercholesterolemia (FH). The panel delivers single nucleotide ... single small panel and allows customisation by ,mix and match, ... for LDLR , P C SK9 ...
(Date:12/8/2016)... ... , ... This CAST literature review and report looks at problems caused by ... economic effects in countries that are major global commodity exporters and importers, which show ... of low level presence (LLP) puts large volumes of trade worth billions of dollars ...
(Date:12/8/2016)... SEOUL, South Korea , Dec. 8, 2016 /PRNewswire/ ... completed a $21 billion KRW (US $18.9M) Series A ... Management, Kolon Investment, G.N. Tech Venture and SNU Bio ... by Eutilex to 30.5 billion KRW (US $27.7M) since ... will help Eutilex to bolster the development and commercialization ...
Breaking Biology Technology: